TWI671011B - A method of tea product manufacturing - Google Patents
A method of tea product manufacturing Download PDFInfo
- Publication number
- TWI671011B TWI671011B TW105144307A TW105144307A TWI671011B TW I671011 B TWI671011 B TW I671011B TW 105144307 A TW105144307 A TW 105144307A TW 105144307 A TW105144307 A TW 105144307A TW I671011 B TWI671011 B TW I671011B
- Authority
- TW
- Taiwan
- Prior art keywords
- tea
- solution
- composite
- ruyi
- persian
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Tea And Coffee (AREA)
Abstract
一種茶產物，其包括綠茶萃取物及如意波斯茶萃取物。其中，綠茶萃取物的多酚及如意波斯茶萃取物的多酚的比例為2：1~6：1。於此，攝取此茶產物可提高生物體的抗氧化能力，進而延緩老化。 A tea product comprising green tea extract and Ruyi Persian tea extract. Among them, the ratio of polyphenols in green tea extract and polyphenols in Ruyi Persian tea extract is 2: 1 ~ 6: 1. Here, ingesting the tea product can improve the antioxidant capacity of the organism, and then delay aging.
Description
本發明關於一種茶類產品的技術，特別是關於一種茶產物及茶產物的製備方法。 The invention relates to the technology of a tea product, in particular to a tea product and a method for preparing a tea product.
老化現象是一種具有普遍性、進行性、累積性及傷害性的內外因素所引發的生理衰退。隨著年齡增加，人體的新陳代謝功能就逐漸減退，且各器官的功能也相對降低。關於老化的原因，至今最著名的理論為自由基理論(free radical theory)。 Aging phenomenon is a kind of physiological decline caused by internal, external and universal factors that are universal, progressive, cumulative and harmful. With the increase of age, the body's metabolic function gradually decreases, and the functions of various organs are relatively reduced. Regarding the cause of aging, the most famous theory so far is free radical theory.
自由基是帶有一個單獨不成對的電子的原子、分子、或離子。自由基可在生物體的任何可進行氧化作用的部位產生，例如，粒腺體。粒腺體是細胞內進行氧化作用且產生能量的主要位置，亦是產生自由基的主要地點。以自由基理論的觀點，由於自由基中不成對的電子為不穩的狀態且具有非常活躍的反應性，而傾向於搶奪其他成對電子中的孤電子，使正常細胞或組織發生連鎖性的氧化反應。當過多自由基引發此類氧化反應時，生物體的防禦系統無法抵抗或調節而導致身體的損害，並且出現老化或疾病的徵兆。提升生物體的抗氧化能力可以有效地減少自由基所造成的傷害，以及延緩生物體的衰老或死亡。可以從飲食中攝取抗氧化物質，例如：維生素E、維生素C、β-胡蘿蔔素與多酚等，以加強人體的抗氧化能力。 Free radicals are atoms, molecules, or ions with a single unpaired electron. Free radicals can be generated in any part of the organism where oxidation can take place, for example, the mitochondria. The mitochondria are the main sites for intracellular oxidation and energy production, as well as the main sites for free radicals. From the viewpoint of free radical theory, because unpaired electrons in free radicals are unstable and have a very active reactivity, they tend to snatch lone electrons from other paired electrons, causing normal cells or tissues to have a linked effect. Oxidation reaction. When too many free radicals trigger such oxidative reactions, the body's defense system cannot resist or regulate and cause damage to the body, and there are signs of aging or disease. Improving the antioxidant capacity of the organism can effectively reduce the damage caused by free radicals and delay the aging or death of the organism. Antioxidants such as vitamin E, vitamin C, β-carotene and polyphenols can be taken from the diet to strengthen the body's antioxidant capacity.
茶為臺灣重要的經濟作物，且以茶葉製成的茶水、茶湯等是消耗量僅次於水的飲料。由於茶含有豐富的多酚類物質，所製得的茶飲料不僅具有特殊香氣與味道，且還能抗氧化或抗癌等。由於茶飲料十分容易取得，因而成為人體攝取抗氧化物質的主要來源之一。然而，如欲自茶飲料中攝取足夠的多酚，則必須大量地飲用茶飲料。 Tea is an important cash crop in Taiwan, and tea, tea soup, etc. made from tea are the beverages that consume second only to water. Because tea is rich in polyphenols, the tea beverage produced not only has special aroma and taste, but also has anti-oxidation or anti-cancer properties. Because tea beverages are very easy to obtain, they have become one of the main sources of antioxidant substances in the body. However, if you want to get enough polyphenols from tea drinks, you must drink tea drinks in large quantities.
在一實施例中，一種茶產物，其包括綠茶萃取物及如意波斯茶萃取物，其中綠茶萃取物的多酚及如意波斯茶萃取物的多酚的比例為2：1~6：1。 In one embodiment, a tea product includes green tea extract and Ruyi Persian tea extract, wherein the ratio of polyphenols in green tea extract and polyphenols in Ruyi Persian tea extract is 2: 1 ~ 6: 1.
在一實施例中，一種茶產物，其包括0.05%至0.5%的綠茶萃取物及0.02%至0.2%的如意波斯茶萃取物。 In one embodiment, a tea product includes 0.05% to 0.5% green tea extract and 0.02% to 0.2% Ruyi Persian tea extract.
在一實施例中，一種茶產物的製備方法，其包括添加0.035%至0.35%的如意波斯茶葉至溶劑中以形成如意波斯茶溶液、添加0.05%至0.5%的綠茶萃取物至該如意波斯茶溶液中以形成複合茶溶液以及純化該複合茶溶液。 In one embodiment, a method for preparing a tea product includes adding 0.035% to 0.35% Ruyi Persian tea to a solvent to form Ruyi Persian tea solution, and adding 0.05% to 0.5% green tea extract to the Ruyi Persian tea. Solution to form a composite tea solution and purify the composite tea solution.
綜上所述，本發明之實施例的茶產物及茶產物的製備方法適用於提供具有來自綠茶及如意波斯茶的二種多酚的茶產物。生物體可以藉由食用此茶產物以提高體內的抗氧化能力，進而延緩老化。 In summary, the tea product and the tea product preparation method according to the embodiments of the present invention are suitable for providing a tea product having two polyphenols from green tea and Ruyi Persian tea. The organism can consume the tea product to improve the antioxidant capacity in the body, thereby delaying aging.
S10‧‧‧形成複合茶溶液 S10‧‧‧forms compound tea solution
S100‧‧‧添加為0.035%至0.35%的如意波斯茶葉至溶劑中，以形成如意波斯茶溶液 S100‧‧‧ Adds Ruyi Persian tea to the solvent at 0.035% to 0.35% to form Ruyi Persian tea solution
S101‧‧‧添加0.05%至0.5%的綠茶萃取物至如意波斯茶溶液中，以形成複合茶溶液 S101‧‧‧ Add 0.05% to 0.5% green tea extract to Ruyi Persian tea solution to form a composite tea solution
S12‧‧‧萃取此複合茶溶液 S12‧‧‧Extract this compound tea solution
S120‧‧‧乾燥此複合茶溶液，以得到複合茶粉 S120‧‧‧ Dry the compound tea solution to obtain compound tea powder
S121‧‧‧攪拌複合茶溶液，以形成初萃液 S121‧‧‧ Stir the compound tea solution to form a primary extract
S122‧‧‧過濾此初萃液 S122‧‧‧Filter this initial extract
S123‧‧‧乾燥此初萃液，以得到複合茶粉 S123‧‧‧ drying the initial extract to obtain compound tea powder
圖1為本發明的一實施例的茶產物的製備方法的流程圖。 FIG. 1 is a flowchart of a method for preparing a tea product according to an embodiment of the present invention.
圖2為本發明的一實施例的茶產物的製備方法的步驟S10的流程圖。 FIG. 2 is a flowchart of step S10 of a method for preparing a tea product according to an embodiment of the present invention.
圖3為本發明的一實施例的茶產物的製備方法的流程圖。 3 is a flowchart of a method for preparing a tea product according to an embodiment of the present invention.
圖4為本發明的一實施例的茶產物的製備方法的步驟S12的流程圖。 FIG. 4 is a flowchart of step S12 of a method for preparing a tea product according to an embodiment of the present invention.
在一些實施例中，茶產物可包括綠茶萃取物以及如意波斯茶(rooibos tea)萃取物。 In some embodiments, the tea product may include green tea extract and rooibos tea extract.
在一些實施例中，可使用溶劑自可利用茶葉及/或以磨碎茶葉而得的茶粉萃取出茶萃取物，且茶萃取物可為固體、液體、漿體、膠體或半固體等的狀態。在一些實施例中，上述溶劑可為水或其他可替代使用的溶劑。 In some embodiments, a solvent may be used to extract a tea extract from tea leaves and / or tea powder obtained by grinding the tea leaves, and the tea extract may be a solid, liquid, slurry, colloid, or semi-solid, etc. status. In some embodiments, the solvent may be water or other solvents that can be used instead.
舉例來說，綠茶萃取物可藉由將綠茶粉溶解於水中以形成綠茶溶液再利用攪拌、過濾、乾燥、濃縮或上述手段的任意組合處理綠茶溶液而獲得的液體或固體。在另一範例中，如意波斯茶萃取物可藉由將如意波斯茶葉浸泡於水中以形成如意波斯茶溶液再利用攪拌、過濾、乾燥、濃縮或上述手段的任意組合處理如意波斯茶溶液而獲得的液體或固體。或者是，將綠茶溶液與如意波斯茶溶液的混合溶液利用攪拌、過濾、乾燥、濃縮或上述手段的任意組合處理後同時獲得液體或固體的綠茶萃取物以及如意波斯茶萃取物。 For example, the green tea extract may be a liquid or solid obtained by dissolving green tea powder in water to form a green tea solution, and then processing the green tea solution by stirring, filtering, drying, concentrating, or any combination of the above methods. In another example, Ruyi Persian tea extract can be obtained by soaking Ruyi Persian tea in water to form Ruyi Persian tea solution and then processing the Ruyi Persian tea solution by stirring, filtering, drying, concentrating or any combination of the above methods Liquid or solid. Alternatively, a mixed solution of green tea solution and Ruyi Persian tea solution is processed by stirring, filtering, drying, concentrating or any combination of the above methods to obtain liquid or solid green tea extract and Ruyi Persian tea extract simultaneously.
在一些實施例中，用以生成如意波斯茶萃取物的茶葉及/或茶粉可以是經過發酵的如意波斯茶葉及/或茶粉、或是未發酵的如意波斯茶葉及/或茶粉與經過發酵的如意波斯茶葉及/或茶粉的混合。 In some embodiments, the tea leaves and / or tea powder used to produce Ruyi Persian tea extract may be fermented Ruyi Persian tea and / or tea powder, or unfermented Ruyi Persian tea and / or tea powder and processed A blend of fermented Ruyi Persian tea and / or tea powder.
在一些實施例中，綠茶萃取物在此茶產物中所佔的重量比例為0.05%至0.5%，且如意波斯茶萃取物在此茶產物中所佔的重量比例為 0.02%至0.2%。在一些實施例中，綠茶萃取物及如意波斯茶萃取物的重量比例可為1：1~5：1。 In some embodiments, the weight proportion of green tea extract in the tea product is 0.05% to 0.5%, and the weight proportion of Ruyi Persian tea extract in the tea product is 0.02% to 0.2%. In some embodiments, the weight ratio of the green tea extract and Ruyi Persian tea extract may be 1: 1 to 5: 1.
在一些實施例中，綠茶萃取物與如意波斯茶萃取物均含有多酚，且綠茶萃取物的多酚及如意波斯茶萃取物的多酚的重量比例可為2：1~6：1。在一些實施例中，綠茶萃取物的多酚及如意波斯茶萃取物的多酚的重量比例可為3：1。例如，在茶產物的總多酚含量中，綠茶萃取物的多酚所佔的重量比例可為67%至85%，且如意波斯茶萃取物的多酚所佔的重量比例可為15%至33%。 In some embodiments, both the green tea extract and the Ruyi Persian tea extract contain polyphenols, and the weight ratio of the polyphenols of the green tea extract and the Ruyi Persian tea extract may be 2: 1 to 6: 1. In some embodiments, the weight ratio of polyphenols of green tea extract and polyphenols of Ruyi Persian tea extract may be 3: 1. For example, in the total polyphenol content of the tea product, the weight proportion of polyphenols in green tea extract may be 67% to 85%, and the weight proportion of polyphenols in Ruyi Persian tea extract may be 15% to 33%.
在一些實施例中，茶產物的總多酚含量可為20毫克/克(mg/g)至50毫克/克。或者，在一些實施例中，茶產物還可包括溶劑(例如：水)，且茶產物的總多酚含量可為80毫克/100毫升(mg/100ml)至160毫克/100毫升。 In some embodiments, the total polyphenol content of the tea product may be 20 milligrams / gram (mg / g) to 50 milligrams / gram. Alternatively, in some embodiments, the tea product may further include a solvent (eg, water), and the total polyphenol content of the tea product may be 80 mg / 100 ml (mg / 100 ml) to 160 mg / 100 ml.
此外，在一些實施例中，茶產物還可包括膳食纖維或其他草本萃取物。膳食纖維可為水溶性膳食纖維及/或非水溶性膳食纖維。舉例來說，膳食纖維可為果膠、樹膠、黏質物、植物膠、海藻膠、寡醣、木質素、植物表皮質、半纖維素、幾丁質、麥芽糊精、其他可替代使用的物質、或上述任意二者或二者以上的組合。在一些實施例中，膳食纖維可為難消化性麥芽糊精(resistant maltodextrin)。並且，當茶產物包含有溶劑時，膳食纖維在此茶產物中所佔的重量比例為1%至5%。 In addition, in some embodiments, the tea product may also include dietary fiber or other herbal extracts. The dietary fiber may be a water-soluble dietary fiber and / or a water-insoluble dietary fiber. For example, dietary fiber may be pectin, gum, slime, vegetable gum, seaweed gum, oligosaccharide, lignin, plant epidermis, hemicellulose, chitin, maltodextrin, and other alternatives. A substance, or any two or more of the foregoing. In some embodiments, the dietary fiber may be resistant maltodextrin. In addition, when the tea product contains a solvent, the weight ratio of dietary fiber in the tea product is 1% to 5%.
參照圖1，在一實施例中，一種茶產物的製備方法，其包括：形成複合茶溶液(步驟S10)以及萃取此複合茶溶液(S12)。複合茶溶液包括綠茶溶液及如意波斯茶溶液。相對於100%的複合茶溶液，綠茶溶 液包括0.05%至0.5%的綠茶萃取物，且如意波斯茶溶液包含0.035%至0.35%的如意波斯茶葉。 Referring to FIG. 1, in an embodiment, a method for preparing a tea product includes forming a composite tea solution (step S10) and extracting the composite tea solution (S12). Compound tea solutions include green tea solutions and Ruyi Persian tea solutions. Relative to 100% compound tea solution, green tea is soluble The liquid includes 0.05% to 0.5% green tea extract, and the Ruyi Persian tea solution contains 0.035% to 0.35% of Ruyi Persian tea.
參照圖2，在步驟S10的一些實施例中，複合茶溶液的形成步驟。首先，添加為0.035%至0.35%的如意波斯茶葉至溶劑中，以形成如意波斯茶溶液(S100)。接著，添加為0.05%至0.5%的綠茶萃取物至如意波斯茶溶液中，以形成複合茶溶液(S101)。上述百分比(%)為重量百分比。在一些實施例中，步驟S100及S101可同時進行或依序進行。換句話說，在一些實施例中，如意波斯茶葉及綠茶萃取物可以同時添加或依序添加。例如，可先將如意波斯茶葉浸泡於水中形成如意波斯茶溶液後，再添加綠茶萃取物於如意波斯茶溶液中。 Referring to FIG. 2, in some embodiments of step S10, a step of forming a composite tea solution. First, Ruyi Persian tea is added to the solvent at 0.035% to 0.35% to form Ruyi Persian tea solution (S100). Next, a green tea extract of 0.05% to 0.5% is added to the Ruyi Persian tea solution to form a composite tea solution (S101). The above percentage (%) is a weight percentage. In some embodiments, steps S100 and S101 may be performed simultaneously or sequentially. In other words, in some embodiments, Ruyi Persian tea and green tea extract may be added simultaneously or sequentially. For example, Ruyi Persian tea can be soaked in water to form Ruyi Persian tea solution, and then green tea extract can be added to Ruyi Persian tea solution.
此外，參照圖3，在步驟S12的一些實施例中，此步驟還可包括乾燥複合茶溶液，以得到複合茶粉(S120)。例如，可利用冷凍乾燥或其他可用的乾燥方式對複合茶粉進行乾燥。 In addition, referring to FIG. 3, in some embodiments of step S12, this step may further include drying the composite tea solution to obtain a composite tea powder (S120). For example, freeze-drying or other available drying methods can be used to dry the composite tea powder.
參照圖4，在步驟S12的一些實施例中，還可包括以下流程。首先，攪拌複合茶溶液，以形成初萃液(S121)。並且，過濾此初萃液(S122)。此外，在步驟S12的一些實施例中，上述流程還可包括乾燥此初萃液，以得到複合茶粉(S123)。例如，可利用冷凍乾燥或其他可用的乾燥方式對此初萃液進行乾燥。 Referring to FIG. 4, in some embodiments of step S12, the following process may be further included. First, the composite tea solution is stirred to form a primary extract (S121). Then, this initial extraction liquid is filtered (S122). In addition, in some embodiments of step S12, the above process may further include drying the primary extract to obtain a composite tea powder (S123). For example, freeze-drying or other available drying methods can be used to dry this primary extract.
在一些實施例中，經過萃取後的複合茶溶液或經過過濾後的初萃液(即，茶產物)可為液體狀且可具有80毫克/100毫升至160毫克/100毫升的總多酚含量。在一些實施例中，經過乾燥後所得的複合茶粉(即，茶產物)可具有20毫克/克至50毫克/克的總多酚含量。 In some embodiments, the extracted composite tea solution or the filtered primary extract (ie, the tea product) may be liquid and may have a total polyphenol content of 80 mg / 100 ml to 160 mg / 100 ml . In some embodiments, the composite tea powder (ie, the tea product) obtained after drying may have a total polyphenol content of 20 mg / g to 50 mg / g.
此外，在一些實施例中，茶產物的製備方法還可包括添加膳食纖維於複合茶溶液、初萃液或複合茶粉中。可依據需求選擇於任一步驟之後進行添加膳食纖維的步驟。例如，可以在步驟S101之後於經過複合茶溶液中添加膳食纖維，或者可以在步驟S121之後於經過過濾後的初萃液中添加膳食纖維。並且，膳食纖維在複合茶溶液或初萃液中所佔的重量比例可為1%至5%。在一些實施例中，膳食纖維可為難消化性麥芽糊精。 In addition, in some embodiments, the method for preparing a tea product may further include adding dietary fiber to a composite tea solution, a primary extract or a composite tea powder. The step of adding dietary fiber can be selected after any step according to requirements. For example, dietary fiber may be added to the composite tea solution after step S101, or dietary fiber may be added to the filtered extract solution after step S121. In addition, the weight ratio of dietary fiber in the composite tea solution or the initial extract may be 1% to 5%. In some embodiments, the dietary fiber may be indigestible maltodextrin.
此外，在一些實施例中，可依據需求而選擇性地添加單寧分解酵素。單寧分解酵素在茶產物中所佔的重量百分比可為0.001%至0.01%。 In addition, in some embodiments, a tannin-degrading enzyme may be selectively added according to demand. The weight percentage of the tannin-degrading enzyme in the tea product may be 0.001% to 0.01%.
舉例來說，首先，添加13公斤的如意波斯茶葉、13公斤的綠茶萃取物及0.3公斤的單寧分解酵素在4000公升的水中，以形成複合茶溶液。接著，在57℃下攪拌複合茶溶液約30分鐘，且對攪拌後的複合茶溶液進行過濾，以形成初萃液。最後，添加360公斤的難消化性麥芽糊精於初萃液中，以得到茶液(即，液體狀的茶產物)。最後，將茶液利用冷凍乾燥的方式製成複合茶粉(即，粉末狀的茶產物)。每100毫升的茶液可得到3.8公克的茶粉，且茶粉中含有0.13克的綠茶萃取物、0.07克的如意波斯茶萃取物以及3.6克的難消化性麥芽糊精。 For example, first, add 13 kg of Ruyi Persian tea, 13 kg of green tea extract, and 0.3 kg of tannin decomposing enzyme in 4000 liters of water to form a composite tea solution. Next, the composite tea solution is stirred at 57 ° C. for about 30 minutes, and the stirred composite tea solution is filtered to form an initial extract. Finally, 360 kg of indigestible maltodextrin was added to the priming liquid to obtain a tea liquid (ie, a liquid tea product). Finally, the tea liquid is made into a composite tea powder (ie, a powdered tea product) by freeze-drying. For every 100 milliliters of tea solution, 3.8 grams of tea powder can be obtained, and the tea powder contains 0.13 grams of green tea extract, 0.07 grams of Ruyi Persian tea extract, and 3.6 grams of indigestible maltodextrin.
再者，將上述製得的茶粉餵食老化促進傾向-8品系(senescence-accelerated mouse prone-8,SAMP8)小鼠，藉以測試及評估小鼠的老化程度及器官組織的抗氧化能力。 Furthermore, the tea powder prepared above was fed to mice of the senescence-accelerated mouse prone-8 (SAMP8) strain to test and evaluate the degree of aging of mice and the antioxidant capacity of organs and tissues.
將小鼠飼養於動物房內的30×20×10立方公分的透明塑膠籠中，且動物房的溫度為25±2℃、相對濕度為65±5%、黑暗期(dark period) 設定為07：00~19：00以及光照期(light period)設定為19：00~07：00。將3月齡的SAMP8小鼠分為4組(A組、B組、C組及D組)。其中，A組的SAMP8小鼠餵食滅菌水(ddH2O)、B組的SAMP8小鼠是以1.365克/公斤體重/天(g/BW/day)劑量餵食上述茶粉、C組的SAMP8小鼠是以2.73克/公斤體重/天劑量餵食上述茶粉及D組的SAMP8小鼠是以5.46克/公斤體重/天劑量餵食上述茶粉。每組小鼠的數量分別為15隻雄性小鼠及15隻雌性小鼠。此外，餵食頻率為每日一次，且餵食期間為12週。 The mice were housed in a transparent plastic cage of 30 × 20 × 10 cm in the animal room, and the temperature in the animal room was 25 ± 2 ° C, the relative humidity was 65 ± 5%, and the dark period was set to 07. 0: 00 ~ 19: 00 and the light period (light period) is set from 19:00 to 07:00. Three-month-old SAMP8 mice were divided into 4 groups (groups A, B, C, and D). Among them, SAMP8 mice in group A were fed with sterilized water (ddH 2 O), SAMP8 mice in group B were fed the above tea powder at a dose of 1.365 g / kg body weight per day (g / BW / day), and SAMP8 in group C was small. The rats were fed the tea powder at a dose of 2.73 g / kg body weight / day and the SAMP8 mice of group D were fed the tea powder at a dose of 5.46 g / kg body weight / day. The number of mice in each group was 15 male mice and 15 female mice, respectively. In addition, the feeding frequency was once a day, and the feeding period was 12 weeks.
於第12週時，對上述各組中的雄性小鼠及雌性小鼠進行個別老化特徵的老化指數(aging score)的評估及單次被動迴避試驗(single-trial passive avoidance test)。於第13週時，對上述各組中的雄性小鼠及雌性小鼠進行主動迴避試驗(active shuttle avoidance test)。在完成主動迴避試驗後，使各組小鼠禁食8小時。接著，以眼窩採血的方式犧牲小鼠，並且取出其器官組織，以進行腦部組織老化及肝臟組織老化的生物活性指標測定。 At the 12th week, male mice and female mice in each of the above groups were evaluated for their aging scores (aging scores) and single-trial passive avoidance tests. At the 13th week, an active shuttle avoidance test was performed on male and female mice in each group. After completing the active avoidance test, the mice in each group were fasted for 8 hours. Next, the mice were sacrificed by taking blood from the eye sockets, and their organs and tissues were removed to measure the biological activity indicators of brain tissue aging and liver tissue aging.
老化指數是用來評估SAM品系小鼠的衰老程度，評估的項目包括行為(behavior)方面的探索反應(reactivity)及逃避反應(passivity)、外表(appearance)方面的毛髮光澤度(glossiness)、毛髮粗糙度(coarseness)、毛髮脫落(hair loss)及皮膚潰瘍(ulcer)、眼睛(eyes)方面的眼睛水腫(periophthalmic lesion)以及脊椎(spine)方面的前後彎(lordokyphosis)的變化。每個項目具有0、1、2、3及4的5個等級。依據各個項目的等級所公訂的標準定義以評定各組小鼠的老化指數以及計算老化指數的總分。當所評估的項目的分數愈高時，則表示此 項目所屬的老化特徵愈顯著且老化程度愈嚴重。 The aging index is used to evaluate the aging degree of SAM strain mice. The evaluation items include behavioral reactivity and avoidance, appearance, hair glossiness, and hairiness. Changes in coarseness, hair loss, and skin ulcers, periophthalmic lesions in eyes, and spinal lordokyphosis. Each item has 5 levels of 0, 1, 2, 3 and 4. According to the standard definition of each item's grade, the aging index of each group of mice is evaluated and the total score of the aging index is calculated. The higher the score for the item being evaluated, the The more significant the aging characteristics of the project and the more severe the aging.
由表1及表2可知，B、C及D組的雄性小鼠在毛髮粗糙、毛髮脫落及老化指數總分均低於A組的雄性小鼠。B、C及D組的雌性小鼠在毛髮脫落及老化指數總分均低於A組的雌性小鼠。 As can be seen from Tables 1 and 2, male mice in groups B, C, and D had lower hair scores, hair loss, and total aging index scores than male mice in group A. Female mice in groups B, C and D had lower hair loss and lower total aging index scores than female mice in group A.
8-羥基-2’-去氧鳥嘌呤核苷為腦部組織中粒線體基因受到損傷時的產物，且可作為腦部組織老化的生物活性指標物質。取小鼠的腦部組織並分別觀察A組、B組、C組及D組的雄性小鼠及雌性小鼠的粒線體基因中8-羥基-2’-去氧鳥嘌呤核苷(8-hydroxy-2-deoxyguanosine,8-OHdG)的含量，如下表3。 8-Hydroxy-2'-deoxyguanosine is a product of the mitochondrial gene in brain tissue when it is damaged, and it can be used as a biological activity indicator substance for brain tissue aging. Take the brain tissue of mice and observe the 8-hydroxy-2'-deoxyguanosine nucleoside (8-hydroxy-2'-deoxyguanosine nucleoside (8) in male and female mice of groups A, B, C and D respectively. -hydroxy-2-deoxyguanosine, 8-OHdG), as shown in Table 3 below.
由表3中可知，不論性別，當以茶粉為餵食小鼠的劑量愈高時，在小鼠的腦部組織中所測得的8-羥基-2’-去氧鳥嘌呤核苷的含量就愈低。 As can be seen from Table 3, regardless of gender, the higher the dose of tea powder for feeding mice, the higher the content of 8-hydroxy-2'-deoxyguanosine measured in the brain tissue of mice. The lower.
對各組小鼠進行單次被動迴避試驗，以測試各組小鼠滯留於明室(light compartment)中的時間變化，如下表4及表5。若小鼠滯留於明室的時間愈長則表示其學習記憶力愈佳。表4為各組的雄性小鼠進行單次被動迴避試驗的結果，而表5為各組的雌性小鼠的試驗結果。 A single passive avoidance test was performed on each group of mice to test the time variation of the mice in the light compartment, as shown in Tables 4 and 5 below. The longer the mouse stays in the bright room, the better its learning and memory. Table 4 shows the results of a single passive avoidance test for male mice in each group, and Table 5 shows the test results for female mice in each group.
由表4及表5可知，雄性小鼠及雌性小鼠經過24小時的學習後，B組、C組及D組的小鼠停留於明室的時間較A組小鼠為長，尤其雄性小鼠更為顯著。 As can be seen from Tables 4 and 5, after 24 hours of learning in male and female mice, the mice in groups B, C, and D stayed in the bright room longer than the mice in group A, especially the males. Rats are more prominent.
對各組小鼠進行主動迴避試驗，以測試各組小鼠迴避反應(avoidance response)的次數變化。表6為各組的雄性小鼠進行主動迴避試驗的結果，而表7為各組的雌性小鼠的試驗結果。 An active avoidance test was performed on each group of mice to test the change in the number of avoidance responses in each group of mice. Table 6 shows the results of active avoidance tests performed by male mice of each group, and Table 7 shows the test results of female mice of each group.
若小鼠的成功迴避反應的次數愈多則表示其學習記憶力愈佳。由表6及表7中可知，在第二天及第三天時，B組、C組及D組的雄性小鼠的成功迴避反應次數均較A組的雄性小鼠多，且雌性小鼠亦同。隨著茶粉的使用劑量愈多，成功迴避反應的次數愈多。 The greater the number of successful avoidance responses in a mouse, the better its learning and memory. As can be seen from Tables 6 and 7, on the second and third days, the number of successful avoidance responses of male mice in groups B, C, and D was more than that of male mice in group A, and female mice The same. As the amount of tea powder used increases, the number of successful avoidance reactions increases.
超氧化物歧化酵素(Superoxide dismutase,SOD)及麩胱苷肽過氧化酵素(glutathione peroxidase,GPx)的活性為與肝臟抗氧化程度相關的生化指標。取小鼠的肝臟組織並分別測試各組雄性小鼠及雌性小鼠的超氧化物歧化酵素及麩胱苷肽過氧化酵素在肝臟中的活性。表8為各組的雄性小鼠及雌性小鼠的肝臟組織中超氧化物歧化酵素的活性的測試結果。表9為各組的雄性小鼠及雌性小鼠的肝臟組織中麩胱苷肽過氧化酵素的活性的測試結果。 The activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx) are biochemical indicators related to the degree of liver oxidation. The liver tissues of mice were collected and tested for the activities of superoxide dismutase and glutathione peroxidase in the liver of male and female mice in each group. Table 8 shows the test results of the activity of superoxide dismutase in liver tissues of male and female mice of each group. Table 9 shows the test results of the activity of glutathione peroxidase in liver tissues of male and female mice of each group.
由表8及表9可知，B組、C組及D組的雄性小鼠及雌性小鼠的肝臟中超氧化物歧化酵素及麩胱苷肽過氧化酵素的活性均較A組為高。可知在小鼠攝取茶粉後確實可提高肝臟超氧化物歧化酵素與麩胱苷肽過氧化酵素的活性，且隨著攝取茶粉的劑量愈高，超氧化物歧化酵素與麩胱苷肽過氧化酵素的活性就愈高。 As can be seen from Tables 8 and 9, the activities of superoxide dismutase and glutathione peroxidase in the livers of male and female mice of groups B, C, and D were higher than those of group A. It is known that the tea superoxide dismutase and glutathione peroxidase activity in liver can be increased after mice ingested tea powder, and the higher the dose of tea powder, the higher the amount of superoxide dismutase and glutathione The higher the activity of oxidative enzymes.
總言之，本發明之實施例的茶產物及茶產物的製備方法適用於提供具有來自綠茶及如意波斯茶的二種多酚的茶產物，以致生物體可藉由攝取低劑量的茶產物以提高體內的抗氧化能力，進而降低細胞或器官的衰退速率，進而延緩老化。 In summary, the tea product and the tea product preparation method of the embodiment of the present invention are suitable for providing a tea product having two polyphenols from green tea and Ruyi Persian tea, so that an organism can ingest a low dose of the tea product to Improves the body's antioxidant capacity, which in turn reduces the rate of cell or organ decline and delays aging.
雖然本發明的技術內容已經以較佳實施例揭露如上，然其並非用以限定本發明。任何熟悉此技藝者，在不脫離本發明之精神所作些許之更動與潤飾，皆應涵蓋於本發明的範疇內。因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。 Although the technical content of the present invention has been disclosed as above with preferred embodiments, it is not intended to limit the present invention. Any modification and retouching made by those skilled in the art without departing from the spirit of the present invention should be included in the scope of the present invention. Therefore, the protection scope of the present invention shall be determined by the scope of the appended patent application.
Claims (9)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW105144307A TWI671011B (en) | 2016-12-30 | 2016-12-30 | A method of tea product manufacturing |
| CN201710090889.0A CN108260685B (en) | 2016-12-30 | 2017-02-20 | Tea product and method for producing tea product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW105144307A TWI671011B (en) | 2016-12-30 | 2016-12-30 | A method of tea product manufacturing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201822641A TW201822641A (en) | 2018-07-01 |
| TWI671011B true TWI671011B (en) | 2019-09-11 |
Family
ID=62770856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105144307A TWI671011B (en) | 2016-12-30 | 2016-12-30 | A method of tea product manufacturing |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN108260685B (en) |
| TW (1) | TWI671011B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248390B1 (en) * | 2000-02-22 | 2001-06-19 | Suzanne Jaffe Stillman | Fiber-water—water containing soluble fiber |
| WO2010014846A1 (en) * | 2008-07-30 | 2010-02-04 | T & T Enterprises Inc. | Antioxidant additive |
| CN103704423A (en) * | 2014-01-02 | 2014-04-09 | 绿锦发展(福建)有限公司 | Preparation method for tea extract |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1781113A1 (en) * | 2004-07-29 | 2007-05-09 | The University of Stellenbosch | A process of producing rooibos tea extract |
| PL2575503T3 (en) * | 2010-06-04 | 2014-08-29 | Unilever Nv | Product comprising catechins |
-
2016
- 2016-12-30 TW TW105144307A patent/TWI671011B/en active
-
2017
- 2017-02-20 CN CN201710090889.0A patent/CN108260685B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248390B1 (en) * | 2000-02-22 | 2001-06-19 | Suzanne Jaffe Stillman | Fiber-water—water containing soluble fiber |
| WO2010014846A1 (en) * | 2008-07-30 | 2010-02-04 | T & T Enterprises Inc. | Antioxidant additive |
| CN103704423A (en) * | 2014-01-02 | 2014-04-09 | 绿锦发展(福建)有限公司 | Preparation method for tea extract |
Non-Patent Citations (1)
| Title |
|---|
| Gadow, A. von Joubert, E. and Hansmann, C.F. , "Comparison of the antioxidant activity of rooibos tea (Aspalathus linearis) with green, oolong and black tea", Food Chemistry, Vol. 60, No.1, September 1996, page 73-77. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108260685A (en) | 2018-07-10 |
| CN108260685B (en) | 2021-09-03 |
| TW201822641A (en) | 2018-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gâtlan et al. | Sea buckthorn in plant based diets. An analytical approach of sea buckthorn fruits composition: Nutritional value, applications, and health benefits | |
| Alimi et al. | Protective effect of Opuntia ficus indica f. inermis prickly pear juice upon ethanol-induced damages in rat erythrocytes | |
| Gorinstein et al. | The effects of diets, supplemented with either whole persimmon or phenol-free persimmon, on rats fed cholesterol | |
| Teng et al. | Anti-fatigue effect of green tea polyphenols (-)-epigallocatechin-3-gallate (EGCG) | |
| Anjum et al. | Nutraceutical application and value addition of banana (Musa paradisica L. Variety “bhusawal keli”) peel: A review | |
| Rana et al. | Multifunctional properties of polysaccharides from Dalbergia sissoo, Tectona grandis and Mimosa diplotricha | |
| Oibiokpa et al. | Nutritional composition of Detarium microcarpum fruit. | |
| CN103652859B (en) | A kind of health food with anti-oxidation function and preparation method thereof | |
| KR102020586B1 (en) | Healthy foods for elderly comprising animal and plant extracts and process for preparation thereof | |
| Lim et al. | Potential functional byproducts from guava puree processing | |
| Basumatary et al. | Nutritional value, phytochemicals and antioxidant property of six wild edible plants consumed by the Bodos of North-East India | |
| Salazar‐López et al. | Health benefits of spent coffee grounds | |
| US20090280203A1 (en) | COMPOSITIONS OF ATOMIZED OR LYOPHILIZED MACA (Lepidium meyenii) EXTRACTS AND ATOMIZED OR LYOPHILIZED YACON (Smallanthus sanchifolius) EXTRACTS AS ADJUVANTS IN THE TREATMENT OF DIFFERENT CONDITIONS | |
| Hu et al. | Water and alcohol extracts from Diaphragma juglandis on anti‐fatigue and antioxidative effects in vitro and vivo | |
| KR102422527B1 (en) | Supplement food composition for diet | |
| CN102499300B (en) | Solid tea having antioxidation function and preparation method thereof | |
| TWI671011B (en) | A method of tea product manufacturing | |
| Chintu et al. | In-vitro antioxidant and antidiabetic activity of hydro alcoholic extract of Opuntia elatior fruit as well as quercetin | |
| KR101503429B1 (en) | Preparation method of cassia tora l. with improved antioxidant activity by using roasting | |
| KR20110037020A (en) | The anti-diabetes composition containing silkworm culturing product and medicinal herbs | |
| KR101073624B1 (en) | Compositions comprising young Phragmites communis leaves or extracts thereof for preventing or improving obesity, or antioxidant activity | |
| Esan et al. | The Effects of okra (Abelmoschus esculentus (L) M oench) fruit extracts on diabetes markers in streptozotocin-induced diabetic rats. Arch | |
| Airaodion et al. | Chemical Composition and Nutraceutical Potential of Velvet Tamarind (Dialium guineense wild) Fruit Pulp | |
| Igbokwe et al. | Tetracarpidium conophorum extract exhibits anti-fatigue activity in rats via reduced protein catabolism, increased antioxidant status and delayed lactate elevation | |
| PEKER et al. | Benfluorex, friends or foe? The effects of Benfluorex on oxidative status in the brain during experimental diabetes |